Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
M. R. V. Ikoma,Miriam P Beltrame,Silvia Inês Alejandra Cordoba Pires Ferreira,Elizabeth Xisto Souto,Mariester Malvezzi,Mihoko Yamamoto +5 more
Reads0
Chats0
TLDR
It is recommended that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.Abstract:
Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.read more
Citations
More filters
Journal ArticleDOI
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients.
Prashant Tembhare,Papagudi G Subramanian Pg,Sitaram Ghogale,Gaurav Chatterjee,Nikhil Patkar,Avinash Gupta,Rahul Shukla,Yajamanam Badrinath,Nilesh Deshpande,Gaurav Narula,Pearl Rodrigues,Karishma Girase,Dilshad Dhaliwal,Maya Prasad,Dhanalaxmi Shetty,Shripad Banavali,Sumeet Gujral +16 more
TL;DR: A highly sensitive, widely applicable, and easily reproducible FC‐MRD assay is needed, which can provide a reliable basis for therapeutic modifications.
Journal ArticleDOI
Normal variation of bone marrow B-cell precursors according to age - reference ranges for studies in myelodysplastic syndromes in Brazil.
Irene Lorand-Metze,Ana Leda F. Longhini,Gislaine Oliveira-Duarte,Rodolfo Patussi Correia,Maria Cláudia Santos-Silva,Mihoko Yamamoto,Alex Freire Sandes,A.F. Oliveira,E X Souto,M. R. V. Ikoma,Fernanda Gonçalves Pereira-Cunha,Miriam P Beltrame,Konradin Metze +12 more
TL;DR: To assess the normal values according to age became important as BCPs are decreased in myelodysplastic syndromes and have been considered an important diagnostic and prognostic feature in these clonal disorders.
Journal ArticleDOI
Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation.
TL;DR: The combined usage of MFC and WT1 monitoring contributed to an improved detection rate of relapse and may be used to monitor MRD, assess the treatment efficacy and prognosis, and predict the risk of recurrence in leukemia patients without specific molecular markers after allogeneic hematopoietic stem cell transplantation.
Journal ArticleDOI
How I investigate minimal residual disease in acute lymphoblastic leukemia.
Rodolfo Patussi Correia,Laiz Cameirão Bento,Flávia Arandas de Sousa,Rodrigo de Souza Barroso,Paulo Vidal Campregher,Nydia Strachman Bacal +5 more
TL;DR: A review of the methodological approaches to measure minimal residual disease (MRD) in ALL and discuss the advantages and limitations of the most commonly used techniques can be found in this paper.
Journal ArticleDOI
Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA - 2009 protocol.
Juliana Maria Camargos Rocha,S. Xavier,Marcelo Eduardo de Lima Souza,Mitiko Murao,Benigna Maria de Oliveira +4 more
TL;DR: Results show that FC and standard PCR produce similar results in MRD detection of childhood ALL and that both methodologies may be useful in the monitoring of disease treatment, especially in regions with limited financial resources.
References
More filters
Journal ArticleDOI
Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Hélène Cavé,van der Werff ten Bosch J,Stefan Suciu,C. Guidal,C Waterkeyn,Jacques Otten,Marleen Bakkus,Kris Thielemans,Bernard Grandchamp,Etienne Vilmer +9 more
TL;DR: Residual leukemia after induction of a remission is a powerful prognostic factor in childhood ALL and detection of residual disease by PCR should be used to identify patients at risk for relapse and should be taken into account in considering alternative treatment.
Journal ArticleDOI
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Michael J. Borowitz,Meenakshi Devidas,Stephen P. Hunger,W. Paul Bowman,W. Paul Bowman,Andrew J. Carroll,William L. Carroll,Stephen B. Linda,Paul L. Martin,D. Jeanette Pullen,David S. Viswanatha,Cheryl L. Willman,Naomi J. Winick,Bruce M. Camitta +13 more
TL;DR: Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis and associated with shorter event-free survival (EFS) in all risk groups; even patients with 0.1% day-29 MRD had poor outcome compared with patients negative for MRD patients.
Journal ArticleDOI
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
Tomas Kalina,Juan Flores-Montero,V H J van der Velden,Marta Martin-Ayuso,S Böttcher,Matthias Ritgen,Julia Almeida,Ludovic Lhermitte,Vahid Asnafi,Alexandre de Mendonça,R de Tute,M Cullen,Lukasz Sedek,M B Vidriales,J.J. Pérez,J. G. te Marvelde,Ester Mejstrikova,Ondrej Hrusak,T Szczepa nacute,ski,J. J. M. Van Dongen,Alberto Orfao +21 more
TL;DR: The 6 years of extensive collaborative experiments and the analysis of hundreds of cell samples of patients and healthy controls have provided for the first time laboratory protocols and software tools for fully standardized 8-color flow cytometric immunophenotyping of normal and malignant leukocytes in bone marrow and blood; this has yielded highly comparable data sets, which can be integrated in a single database.
Journal ArticleDOI
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Thomas Flohr,Thomas Flohr,André Schrauder,Giovanni Cazzaniga,Renate Panzer-Grümayer,V H J van der Velden,Susanna Fischer,Martin Stanulla,Giuseppe Basso,Felix Niggli,Beat W. Schäfer,Rosemary Sutton,Rolf Koehler,Martin Zimmermann,Maria Grazia Valsecchi,Helmut Gadner,Giuseppe Masera,Martin Schrappe,J. J. M. Van Dongen,Andrea Biondi,Claus R. Bartram +20 more
TL;DR: In conclusion, MRD-PCR-based stratification using stringent criteria is feasible in almost 80% of patients in an international multicenter trial.
Journal ArticleDOI
Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry.
TL;DR: Hematogones always exhibited a typical complex spectrum of antigen expression that defines the normal antigenic evolution of B-cell precursors and lacked aberrant expression, and lymphoblasts in 49 cases of precursor B-ALL showed maturation arrest and exhibited 1 to 11 immunophenotypic aberrancies.